Hormone Therapy Linked to Higher Risk of Breast Cancer
According to a study conducted by the University of Chicago, heightened breast cancer risks tied to hormone therapy (HRT) may is dependent on body mass index (BMI), race and breast density.
Hormone Therapy and Breast Cancer
- A number of previous studies have found that hormone therapy used to reduce the symptoms associated with menopause may be linked to increased risk of breast cancer.
- Because of such studies, doctors observed a decreased number of women being prescribed hormone therapy, and a decline in breast cancer rates shortly after.
- A new study carried out by the University of Chicago sought to identify risk groups among those women who participate in hormone therapy.
- To do so, researchers gathered information on over 1.65 million postmenopausal women ages 45 and older.
Increase Risks of Breast Cancer from Hormone Therapy Varies
“The true effect of long-term HRT use on breast-cancer risk might be higher than observed, especially in subgroups of women identified to be sensitive to HRT.” – Study researchers as published by Fox News
- The study found that increased risk of breast cancer among women prescribed hormone therapy varied dependent on body mass index (BMI), race and breast density.
- Among underweight and normal weight woman (BMI below 25), those who used hormone therapy saw a 35 percent increase in breast cancer risk over those who did not use hormone therapy.
- In obese women (BMI above 30) the risk of breast cancer was not affected.
- Women with extremely dense breasts (women with more connective tissue relative to the amount of fat tissue in their breast) experienced a 40 percent increase in breast cancer risk while on hormone therapy.
- Hispanic and white woman saw a 20 percent increase, while black woman were not affected.
- The study did not long at the amount of time each woman was using hormone therapy.
Contact an Experienced Product Liability Attorney
Thomas J. Henry are leaders in the area of drug and product liability litigation. Our Defective Drug and Products Division have extensive knowledge and resources in order to represent our clients efficiently and aggressively. The Defective Drug and Products Division represent a multitude of people who are battling against manufacturers of medical devices and/ or defective pharmaceuticals.
If you or a loved one have been injured by or have developed serious side-effects from the use of defective medications or pharmaceuticals, contact Thomas J. Henry immediately. We represent clients/victims all over the country. We are available 24/7, nights and weekends.